PTK2 and kidney cancer: Studies comparing metastatic and non-metastatic kidney cancers have reported a 2 to 2.5-fold overexpression of FAK and paxillin mRNA in metastatic cases, further reinforcing the critical role of FAK in promoting metastasis in ccRCC [37].